Entacapone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Entacapone: From Parkinson’s Disease to PLA2G6-Associated Neurodegeneration
One-Sentence Summary
Entacapone is a peripheral COMT inhibitor originally used as an adjunct to levodopa/carbidopa therapy for Parkinson’s disease. The TxGNN model predicts it may be effective for PLA2G6-associated neurodegeneration, but this is currently a pure model prediction with 0 clinical trials and 0 publications supporting the link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson’s Disease (adjunctive therapy with levodopa/carbidopa) |
| Predicted New Indication | PLA2G6-associated neurodegeneration |
| TxGNN Prediction Score | 99.76% |
| Evidence Level | L5 |
| Taiwan Market Status | Not marketed |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the source record (drug.original_moa is flagged as a data gap). However, based on the repurposing rationale annotations attached to other candidates in this evidence pack, entacapone’s established clinical role is as a peripheral catechol-O-methyltransferase (COMT) inhibitor, used to prolong the central availability of levodopa in Parkinson’s disease. It does not cross the blood-brain barrier and has no known direct disease-modifying action of its own.
PLA2G6-associated neurodegeneration (PLAN) is a genetic neurodegenerative disorder; its adult-onset form can present with parkinsonian symptoms. The theoretical link proposed by TxGNN is that patients with this parkinsonian phenotype might, like Parkinson’s disease patients, be managed with levodopa-based regimens in which entacapone could serve as an adjunct. This is a plausible symptomatic-management hypothesis rather than a disease-modifying mechanism, and it is not supported by any clinical or literature evidence at this time — the connection should be treated as a knowledge-graph-derived hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Taiwan Market Information
Entacapone currently has no marketing authorization on file in Taiwan (market status: not marketed; 0 licenses recorded). No approved indication text is available from local regulatory data.
Safety Considerations
Please refer to the package insert for safety information. Note: TFDA label warnings/contraindications are marked as a Blocking data gap (DG001) — this must be resolved before any formal safety (S1) evaluation can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction rests solely on a TxGNN knowledge-graph score (L5, decision stage S0), with zero supporting clinical trials or literature after targeted searches. Combined with a blocking data gap on TFDA safety labeling, there is currently no basis to advance this candidate beyond hypothesis stage.
To proceed, the following is needed:
- TFDA label PDF (warnings/contraindications) — DG001, blocking
- Confirmed mechanism of action from DrugBank — DG002
- Preclinical or case-level evidence linking COMT inhibition to PLA2G6-associated neurodegeneration symptom management
- Note: other predicted indications for entacapone in this evidence pack — Lewy body dementia (rank 7) and progressive supranuclear palsy-corticobasal syndrome (rank 10) — reached decision stage S1 with at least weak trial/literature signals, and may be a more productive focus than this rank-1 candidate if resources are limited.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.